TY - JOUR. T1 - VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma. T2 - A Wisconsin Oncology Network study. AU - Chang, Julie E.. AU - Peterson, Christopher. AU - Choi, Sangbum. AU - Eickhoff, Jens C.. AU - Kim, Kyungmann. AU - Yang, David T.. AU - Gilbert, Leslie A.. AU - Rogers, Eric S.. AU - Werndli, Jae E.. AU - Huie, Michael S.. AU - Mcfarland, Thomas A.. AU - Volk, Michael. AU - Blank, Jules. AU - Callander, Natalie S.. AU - Longo, Walter L.. AU - Kahl, Brad S.. PY - 2011/10. Y1 - 2011/10. N2 - Intensive chemotherapy regimens are not feasible in many adults with mantle cell lymphoma (MCL). We sought to build upon our previous experience with a non-intensive regimen, modified R-hyperCVAD chemotherapy (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) with maintenance rituximab (MR), by the incorporation of bortezomib (VcR-CVAD) and the extension of MR beyond 2years. Patients with previously untreated MCL received VcR-CVAD ...
TY - JOUR. T1 - Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma. T2 - Eastern Cooperative Oncology Group study E1499. AU - Smith, Mitchell R.. AU - Li, Hailun. AU - Gordon, Leo. AU - Gascoyne, Randy D.. AU - Paietta, Elisabeth. AU - Forero-Torres, Andres. AU - Kahl, Brad S.. AU - Advani, Ranjana. AU - Hong, Fangxin. AU - Horning, Sandra J.. PY - 2012/9/1. Y1 - 2012/9/1. N2 - Purpose: To test the hypothesis that consolidation therapy with yttrium-90 ( 90Y) -ibritumomab tiuxetan after brief initial therapy with four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated mantle-cell lymphoma would be a well-tolerated regimen that would improve outcomes compared with historical R-CHOP data. Patients and Methods: Patients ≥ 18 years old with histologically confirmed mantle-cell ...
This was a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-sensitive indolent B-cell non hodgkin lymphoma that has relapsed at least 6 months after completing treatment with single agent rituximab or a rituximab-containing regimen. Subjects must have attained a Complete Response or Partial Response to their last prior rituximab containing therapy lasting at least six months beyond the end of rituximab therapy. Subjects were to receive four weekly doses of single agent ofatumumab (1000 mg) or rituximab (375 mg/m2), followed by ofatumumab (1000 mg) or rituximab (375 mg/m2) every 2 months for four additional doses. Therefore, subjects were to receive a total of eight doses of anti-CD20 antibody over 9 months. Subjects were evaluated for response after completion of the first four doses of therapy, after six doses of therapy, and after completion of study ...
This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-sensitive indolent B-cell non hodgkin lymphoma that has relapsed at least 6 months after completing treatment with single agent rituximab or a rituximab-containing regimen. Subjects must have attained a Complete Response or Partial Response to their last prior rituximab containing therapy lasting at least six months beyond the end of rituximab therapy. Subjects will receive four weekly doses of single agent ofatumumab (1000 mg) or rituximab (375 mg/m2), followed by ofatumumab (1000 mg) or rituximab (375 mg/m2) every 2 months for four additional doses. Therefore, subjects will receive a total of eight doses of anti-CD20 antibody over 9 months. Subjects will be evaluated for response after completion of the first four doses of therapy, after six doses of therapy, and after completion of study therapy. ...
The treatment of non-Hodgkin lymphoma (NHL) patients has been recently informed by several important studies, which were discussed at the Best of ASCO Boston meeting by Michael E. Williams, MD, of the University of Virginia Cancer Center in Charlottesville.. Bendamustine Outperforms R-CHOP in NHL In a presentation at this years ASCO Annual Meeting Plenary Session, German investigators reported that in the phase III Study Group Indolent Lymphomas (StiL) NHL1 trial, the combination of bendamustine (Treanda) plus rituximab (Rituxan), or BR, more than doubled the median progression-free survival vs standard treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and proved more tolerable as well in patients with NHL.1 While B-R has been a recommended treatment option by the National Comprehensive Cancer Network since the initial study data were announced in 2009, many U.S. oncologists have not yet utilized the regimen.. The updated StiL NHL1 results will likely ...
We thank Dr Wallace et al for their response to our recently published article Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis, highlighting some methodological limitations of our study.1 2 One of the limitations mentioned by Wallace and colleagues is the inclusion of incident and prevalent cases and since only 15 out of 192 patients were incident cases, generalisability of our findings for this subset of patients may not be possible. We agree that the use of immunosuppression prior to initiation of rituximab likely confers a risk to develop infectious complications after rituximab administration. Cyclophosphamide was used to control disease in 62 patients the year before rituximab was initiated. Among these, 53 patients had no severe infection (median cyclophosphamide exposure 7 g, range 0.66-45 g), while 9 patients receiving cyclophosphamide the index year before had a severe ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). This new treatment includes the same monoclonal antibody as intravenous Rituxan® (rituximab) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.. "With todays approval of Rituxan Hycela, people with three of the most common blood cancers now have a new treatment option which provides efficacy comparable with intravenous Rituxan and can be delivered under the skin in minutes instead of hours through IV infusion," said Sandra Horning, MD, Roches Chief Medical Officer and Head ...
Paediatric onset multiple sclerosis (POMS) is characterized by high inflammatory activity. No disease modifying treatment has been approved for POMS. The objective of this report was to report the use of rituximab, a B cell depleting monoclonal anti-CD20-antibody, in POMS. This is a retrospective case series at four specialized MS centres in Sweden. Participants were identified through the Swedish MS-registry and our own patient stocks. Data were collected through medical charts review. We identified 14 POMS patients treated with i.v. rituximab 500-1000 mg every 6th to 12th months. Median age at disease onset was 14.7 years, median age at rituximab treatment initiation was 16.5 years, and median treatment duration was 23.6 months. No relapses were reported, and the EDSS scores remained stable or decreased in 13 of 14 cases during rituximab treatment. Beyond 6 months from initiating rituximab treatment, only one new lesion was detected on MRI. No serious AEs were reported. The drug survival was ...
The treatment of patients with non-Hodgkins lymphoma (NHL) may be complicated by concomitant chronic hepatitis C virus (HCV) infection. Recent data suggest that HCV may also be a contributing factor to the development of this disease. Although antiviral treatment has occasionally been reported to result in the regression of lymphoma in patients with HCV infection, the importance of the control of this infection on the prognosis of lymphoma needs to be defined. Here we report a patient with diffuse large B-cell lymphoma who presented with a mass in her left breast. She had had HCV-related liver cirrhosis for 6 years. She was given rituximab monotherapy for three consecutive weeks, but treatment had to be discontinued as a result of hematological toxicity. HCV viral load also increased, but then decreased gradually after rituximab was stopped. She could be given no further therapy. Six months later she presented with spinal involvement with infiltration of the cauda equina. Though cranial-spinal ...
Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with...
In the clinic, BCDT can markedly ameliorate the course of autoimmune diseases in patients, but the mechanisms underlying these beneficial effects are poorly understood, as they are thought, in many cases, to operate irrespective of autoantibody levels. Here, we demonstrate that IL-6 production is the major mechanism of B cell-mediated pathogenesis during EAE, and we show that this inflammatory pathway is markedly increased in RR-MS patients. Autoantibody levels were unaffected by IL-6 production by B cells. This is the first demonstration of a nonantibody-mediated mechanism of B cell pathogenesis in EAE and MS. Remarkably, the elevated production of IL-6 by B cells from MS patients was effectively normalized by Rituximab treatment. In both patients and mice the reduced disease severity after B cell depletion was accompanied by a decrease in the autoreactive Th17 response, and so we believe that B cells are making an all-important contribution to the IL-6-dependent promotion of pathogenic Th17 ...
The present study showed that, in patients with HIV-related DLBCL, immunochemotherapy with R-CHOP with concomitant administration of HAART is feasible, safe and effective. The main prognostic factors were related to the lymphoma itself. In addition, this is the first study to confirm the favourable impact of virological response to HAART in the survival of patients treated with rituximab-based CHT.. The design of this study took into account the promising results observed with standard CHOP CHT in patients with ARL in the HAART era (Coiffier et al, 2002; Pfreundschuh et al, 2006). As immunochemotherapy with rituximab in combination with CHOP-based or infusional regimens has shown good results in non-immunosuppressed patients with DLBCL, we developed the present phase II trial of R-CHOP in this particular subtype of lymphoma in patients with HIV infection, in whom the safety and efficacy were unknown. In fact, to date, only two phase II studies with immunochemotherapy (Spina et al, 2005; Boue et ...
TY - JOUR. T1 - Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma [4]. AU - Ennishi, Daisuke. AU - Yokoyama, Masahiro. AU - Mishima, Yuko. AU - Watanabe, Chie. AU - Terui, Yasuhito. AU - Takahashi, Shunji. AU - Takeuchi, Kengo. AU - Ikeda, Kazuma. AU - Tanimoto, Mitsune. AU - Hatake, Kiyohiko. PY - 2007/11. Y1 - 2007/11. UR - http://www.scopus.com/inward/record.url?scp=36048934446&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=36048934446&partnerID=8YFLogxK. U2 - 10.1080/10428190701636476. DO - 10.1080/10428190701636476. M3 - Article. C2 - 17990181. AN - SCOPUS:36048934446. VL - 48. SP - 2241. EP - 2243. JO - Leukemia and Lymphoma. JF - Leukemia and Lymphoma. SN - 1042-8194. IS - 11. ER - ...
Given the genetic diversity of B-cell lymphomas and differential antigen expression patterns across lymphoma subtypes, it is unlikely that a single small molecule or antibody-based therapeutic will effectively treat all categories of NHL. Therefore, the use of therapeutic antibody combinations targeting different tumor antigens is expected to produce a more robust antitumor response. Simultaneously targeting CD20 and the TNFR family member CD40 may be productive, because both are expressed on the majority of B-cell lymphomas and mediate differential signaling events through their cytoplasmic domains. We evaluated the potential of improving rituximab-based therapies in NHL by targeting CD40 with dacetuzumab. In vivo analysis of the dacetuzumab-rituximab combination in the Ramos NHL xenograft model showed the capacity of dacetuzumab to augment rituximab activity. Potential mechanisms of action behind the ability of dacetuzumab to enhance rituximab activity in vivo include improved recruitment of ...
This study will investigate the efficacy of rituximab IV and seven administrations of rituximab SC (experimental arm) versus four infusions of rituximab IV
This 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and intravenous MabThera (rituximab) in patients with follicular
More than 160 key abstracts confirm MabThera/Rituxan as the standard of care in hematological cancers, , , , Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that updated results of the pivotal phase II...
Whether my decisions ultimately are proved wise will be written in these pages. I began using single-agent rituximab (Rituxan) in 2004, adding the steroid methylprednisolone in March 2007 to combat AIHA. In October 2007, after a severe AIHA relapse that left me steroid refractory, I was treated with Rituxan + cyclophosphamide, vincristine, and prednsione (R-CVP). In January 2009, when AIHA and hemolysis of red blood cells returned, I had Rituxan + cyclophosphamide and dexamethasone (R-CD). I used this a few times to control the condition, with shorter and shorter periods until AIHA relapse. Starting in February 2010 I used Arzerra (ofatumumab) and Revlimid (lenalidomide), and then for a year and a half maintained control of the disease -- and the AIHA -- with Revlimid alone. Alas, the Revlimid came at a high price in terms of blood clotting issues, and as of 2012 I was treated with bendamustine and rituximab, which gave me a CR in the marrow and blood, leaving some swollen lymph nodes behind ...
After three months of Chemo, the Fludarabine/Mitoxantrone is really kicking his bone marrow but its not doing a whole lot to the cancerous lymphocytes, so the new plan is to add Rituxan. Rituxan is a monoclonal antibody which specifically targets mature B Lymphocytes (as opposed to ordinary chemo which kills a lot of "innocent bystander" cells.) This is good news, in my opinion - I was hoping they would try Rituxan soon. But of course, Rituxan has its own sticky wickets, and the first one comes up tomorrow when Dave gets his first dose of Rituxan ...
This finding is in contrast to the more pronounced effect in patients who were RF/anti-CCP seropositive observed in a previous study.11 However, the superior response of patients who were seropositive strengthened over time, as shown by greater decreases in disease activity and enhanced ACR responses at week 48 in rituximab-treated patients who were seropositive compared with patients who were seronegative ...
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with
This prospective, double-blind, placebo-controlled, multi-center, randomized trial will evaluate the effect of rituximab on disease progression in subjects with SSc-PAH receiving concurrent stable-dose standard medical therapy with a prostanoid, endothelin receptor antagonist, and/or phosphodiesterase 5 (PDE-5) inhibitor. The study will focus on assessment of clinical response and safety measures longitudinally. In addition, the effects of treatment with rituximab on the underlying immune mechanisms associated with B-cell dysregulation and pathogenic autoantibody response in this disease will be investigated. 1000 mg of rituximab or placebo will be administered as two IV infusions given two weeks apart. Clinical assessments and sample collection will occur at monthly visits through Week 48. If a participant has not recovered B cells by Week 48, B cell studies will be conducted quarterly until reconstitution is documented or for 2 years after initial treatment. Five patients will be recruited ...
Cost regulators are looking favourably on the use of Roches MabThera on the National Health Service to treat patients with relapsed/refractory forms chronic lymphocytic leukaemia, the most common form of the blood disease. - News - PharmaTimes
Rituximab is a therapy no used in both indolent and aggressive B cell lymphomas. What is the mechanism of action of Rituximab? List the major disorders for which Rituximab is approved for use.. Recall that CD20 is expressed on over 90% of B cells and is a protein that is not shed or internalized.. Rituximab is an anti-CD20 chimeric monoclonal antibody that on contact to CD20 on the surface of a B cell causes cytotoxicity mediated by compliment and antibody-dependent cellular cytotoxicity.. Indications for Rituximab use:. ...
D02994 Rituximab (USAN/INN); Rituximab (genetical recombination) (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN ...
Bulgular: Rituksimab tedavisinin ba lad s rada ortalama ya ( SD) 46,6 11,3 y ld r. Rituksimab tedavisi ncesinde ortalama trombosit say s ( SD) 17,400 8878/mm3 d r. Erken ve ge yan t edilen olgularda rituksimab ba lang c ile yan ta kadar ge en ortalama s re ( SD) s ras yla 1,8 1,3 hafta ve 10 2,8 hafta olarak saptanm t r. EY ve GY elde edilen olgularda ortalama yan t s resi s ras yla 51 47,2 ay ve 6 4,2 ayd r. On be olgunun 7 sinde (%46,7) rituximab tedavisine ba lang ta yan t elde edilmi tir (5 EY, 2 GY). SY oran %26,7 dir (4/15). Rituksimab tedavisine yan t veren olgular aras nda 3 (3/7, %42,9) yan t n bir y ldan fazla ve 2 si (2/7, %28,6) yan t n 5 y ldan fazla s rd rm t r. Yedi olgunun ikisi (%28,6) rituksimab ba lang c ndan 98 ay sonra halen yan t n korumaktad r. Ba lang ta yan t veren 5 olgunun hepsi relaps sonras nda ard k tedavilere yan t vermi tir (3 TY, 2 PY ...
Bulgular: Rituksimab tedavisinin ba lad s rada ortalama ya ( SD) 46,6 11,3 y ld r. Rituksimab tedavisi ncesinde ortalama trombosit say s ( SD) 17,400 8878/mm3 d r. Erken ve ge yan t edilen olgularda rituksimab ba lang c ile yan ta kadar ge en ortalama s re ( SD) s ras yla 1,8 1,3 hafta ve 10 2,8 hafta olarak saptanm t r. EY ve GY elde edilen olgularda ortalama yan t s resi s ras yla 51 47,2 ay ve 6 4,2 ayd r. On be olgunun 7 sinde (%46,7) rituximab tedavisine ba lang ta yan t elde edilmi tir (5 EY, 2 GY). SY oran %26,7 dir (4/15). Rituksimab tedavisine yan t veren olgular aras nda 3 (3/7, %42,9) yan t n bir y ldan fazla ve 2 si (2/7, %28,6) yan t n 5 y ldan fazla s rd rm t r. Yedi olgunun ikisi (%28,6) rituksimab ba lang c ndan 98 ay sonra halen yan t n korumaktad r. Ba lang ta yan t veren 5 olgunun hepsi relaps sonras nda ard k tedavilere yan t vermi tir (3 TY, 2 PY ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe w
Rituximab Coupon- Get your Free Rituximab coupon & Discount Drug Card. Access thousands of free medicine coupons for instant savings.
Pharmaceutical Division: Roches pharmaceuticals division posted a 4% rise in sales to CHF19.5 billion, driven by oncology and immunology medicines, in H1 FY16 at constant exchange rates. U.S. sales grew 4%, led by immunology treatments Xolair and Esbriet, as well as Herceptin and Perjeta against HER2-positive breast cancer. There was robust demand for Alecensa, which was recently launched in the U.S. for a specific type of lung cancer. Sales of Lucentis and Tarceva declined due to competition. In Europe, the 5% sales growth was driven by Perjeta, MabThera/Rituxan and Actemra/RoActemra especially in Germany and France. In the International region, the sales growth of 4% was driven by HER2 medicines, Avastin, and MabThera/Rituxan, partly offset by lower Pegasys sales due to competition from a new generation of hepatitis C treatments. In Japan, sales rose 2% driven by HER2 medicines, Alecensa, and Actemra/RoActemra.. Diagnostics Division: Roches Diagnostics division posted a 6% rise in sales to ...
rituximab: mouse/human chimeric mAB; a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma; has immunosuppressive activity
We thank Yamamoto and colleagues1 for their response to our paper2 and their description of their experience with rituximab (RTX) in IgG4-related disease (IgG4-RD) in three patients. Their letter raises a number of important points pertaining to the management of IgG4-RD, in general, and to the use of B-cell-depletion strategies, specifically.. First, their patients are exemplary of the fact a sizeable subset of IgG4-RD patients has a propensity to disease relapse over time. This point has been underappreciated from early reports of the use of glucocorticoids to treat IgG4-RD because those reports were characterised by short follow-up periods. Although the great majority of patients respond to glucocorticoids initially, repeated disease flares are the rule for many.. Second, patients with IgG4-RD endure substantial morbidity from the requirement for repeated courses (or continuous on treatment) with glucocorticoids. The three patients described by Yamamoto and colleagues are reported to have ...
Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first gener
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL. 
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
This month I had my first two infusions of Rituxan to treat my RRMS and I am wondering how long before I feel better? Should it be immediate - once the B cells are targeted/depleted? Or is there a delay ...
I know the side effects to look for while infusing Rituxan. My question is how does it effect the red count (H&H) after the infusion? Does it lower it as much as some other chemotherapy drugs or
1 Answer - Posted in: rituxan, skin, infusion - Answer: I develop raised hives, used lotion, ice, 2 Benadryl, hydrocortisone cream.
Access important resources on REVLIMID® + rituximab for you and yourpatients. Please see full Prescribing Information, including BoxedWARNINGS on fetal tox, hem tox & blood clots.
Rituximab Helps in Sjgrens Syndrome By Nancy Walsh, Contributing Writer, MedPage Today Published: April 06, 2010 Reviewed by Dori F. Zaleznik, MD;...
maybe its important to test and treat active infections before one starts rituximab and knocks out part of the immune system. active infections would...
CaliReader, thanks. The article reinforces, in part, my thinking as concerns the EBV/MS connection, but also raises new questions. The researchers looked for antibodies. Is it possible to carry the EB virus and not develop antibodies? If so, could whatever ...
Apart from the hair-loss, Im feeling OK although Ive just had a very rough night with tummy issues, which I wont go into here. The new R-Chop regime is easier on me overall, but still comes with its ups and downs ... but overall, Im pleased with the progress and compared to how I was with AVDB treatment and to how rough I felt when I was recovering from my operation, I cannot complain ...
LINTHICUM, MD, October 6, 2016 - The American Urological Association (AUA) and the Urology Care Foundation, together with the Bladder Health Alliance - a coalition of groups representing physicians, patients and veterans - today applauded Sen. Mark Kirk (R-IL) for introducing Senate Resolution 604, a measure supporting the designation of November 2016 as "National Bladder Health Month" in the United States. "The introduction of this resolution by Sen. Kirk is an important step in increasing awareness of bladder conditions," said Dr. Jim Ulchaker, chair of the AUAs Legislative Affairs Committee. "Awareness is one of the first steps toward reducing the stigma associated with bladder conditions and empowering providers and patients to discuss bladder health." Millions of Americans suffer from a variety of bladder health conditions, including urinary incontinence, overactive and underactive bladder, interstitial cystitis, urinary tract infections, nocturia, bladder cancer, urotrauma and neurogenic ...
MZL is a rare type of malignant B-cell lymphoma. Because of the paucity of large clinical trials, the standard treatment for MZL is still a matter of debate. The purpose of this study was to analyze the role of prognostic markers, treatments, and outcomes in a large cohort of 144 patients with MZL who were diagnosed at our institution between 2003 and 2010. Most of our patients (67%) were diagnosed with extranodal MZL, whereas splenic MZL (11%) was the rarest type. Patient with localized disease received radiotherapy and achieved high response rates (CR, 76%). Like in other indolent lymphomas,19 rituximab has demonstrated effectiveness in the treatment of MZL.20-22 However, a prospective randomized trial on this issue is still missing. In our cohort, among those who chose systemic therapy, 79% of patients with nodal MZL and 87% of patients with extranodal MZL received rituximab with or without chemotherapy. Because of the lack of prospective, randomized studies in MZL, the optimal ...
This open-label, randomized study will compare the efficacy of GDC-0199 plus rituximab (GDC-0199+R) with bendamustine plus MabThera/Rituxan (Rituximab) (B+R) in patients with relapsed or resistant chronic lymphocytic leukemia. Patients will be randomized 1:1 into the two arms. Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2).. Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and bendamustine infusions (70 mg/m2) on Days 1 and 2 of each 28-day cycle.. Patients in the GDC-0199+R arm will continue GDC-0199 treatment until disease progression or 2 years since treatment start, whichever comes first. Anticipated time on study is up to 5 years.. ...
TY - JOUR. T1 - Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP. T2 - Report from an International DLBCL Rituximab-CHOP Consortium Program Study. AU - Xu-Monette, Zijun Y.. AU - Wu, Lin. AU - Visco, Carlo. AU - Tai, Yu Chuan. AU - Tzankov, Alexander. AU - Liu, Wei Min. AU - Montes-Moreno, Santiago. AU - Dybkær, Karen. AU - Chiu, April. AU - Orazi, Attilio. AU - Zu, Youli. AU - Bhagat, Govind. AU - Richards, Kristy L.. AU - Hsi, Eric D.. AU - Zhao, X. Frank. AU - Choi, William W.L.. AU - Zhao, Xiaoying. AU - Van Krieken, J. Han. AU - Huang, Qin. AU - Huh, Jooryung. AU - Ai, Weiyun. AU - Ponzoni, Maurilio. AU - Ferreri, Andrés J.M.. AU - Zhou, Fan. AU - Kahl, Brad S.. AU - Winter, Jane N.. AU - Xu, Wei. AU - Li, Jianyong. AU - Go, Ronald S.. AU - Li, Yong. AU - Piris, Miguel A.. AU - Møller, Michael B.. AU - Miranda, Roberto N.. AU - Abruzzo, Lynne V.. AU - Medeiros, L. Jeffrey. AU - Young, Ken H.. PY - 2012/11/8. Y1 - ...
Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be
Incorporating lymphopenia into the Follicular Lymphoma International Prognostic Index (FLIPI) can improve prognostication, according to researchers.